top of page

Clinical experience and outcomes

(Based on data available by October, 2025)
26
Patients treated in IIT and Phase I trial. A further Phase II is in plan. 
No
Vector-related serious AEs reported
Real-world patients treated or in treatment (China program)
50+
Screenshot 2026-01-14 at 09.18.19.png
It is important to note that the following data results depend on patient characteristics, baseline disease burden, and follow-up duration. Eligibility criteria, supportive care, and monitoring vary by center and region. Furthermore, any individual expectations should be discussed thoroughly with your treating physicians.

This website is not intended to diagnose, treat, cure, or prevent any disease, nor to provide medial advice. Treatment decisions should be made with qualified healthcare professional. Availability and eligibility may vary.

WHATSAPP

Tel: +86 157 1005 1714 (GMT +8)

  • Facebook
  • LinkedIn

WECHAT

ID: keeweet (GMT +8)

Kanexthal, X003 or KL003, is owned by Kanglin Biotec (Hangzhou) Co.,Ltd.(referred to as Kanglin Biotec).

bottom of page